Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
WHO. Cancer Fact sheet [online], http://www.who.int/mediacentre/factsheets/fs297/en/ (2017).
Hébuterne X, et al. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014;38:196–204.
WHO. Obesity and overweight fact sheet [online], http://www.who.int/mediacentre/factsheets/fs311/en/ (2016).
Fearon K, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.
Jensen GL, et al. International Consensus Guideline Committee. Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee. JPEN J Parenter Enteral Nutr. 2010;34:156–9.
Dechaphunkul T, et al. Malnutrition assessment in patients with cancers of the head and neck: a call to action and consensus. Crit Rev Oncol Hematol. 2013;88:459–76.
Baracos VE, et al. Cancer-associated cachexia. Nat Rev Dis Prim. 2018;4:17105.
de van der Schueren MAE, et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol. 2018;29:1141–53.
Mourtzakis M, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.
Kazemi-Bajestani SMR, et al. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol. 2016;54:2–10.
Arends J, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48.
Bozzetti F, et al. The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients. Ann Oncol. 2014;25:487–93.
Bozzetti F, et al. Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutrition. Ann Oncol. 2015;26:2335–40.
Crowder SL, et al. Nutrition impact symptoms and associated outcomes in post-chemoradiotherapy head and neck cancer survivors: a systematic review. J Cancer Surviv. 2018. https://doi.org/10.1007/s11764-018-0687-7.
Scott D, et al. Health care professionals’ experience, understanding and perception of need of advanced cancer patients with cachexia and their families: the benefits of a dedicated clinic. BMC Palliat Care. 2016;15:100.
Dev R, et al. Hypermetabolism and symptom burden in advanced cancer patients evaluated in a cachexia clinic. J Cachex- Sarcopenia Muscle. 2015;6:95–98.
Vigano A, et al. The Cachexia Clinic: from staging to managing nutritional and functional problems in advanced cancer patients. Crit Rev Oncog. 2012;17:293–304.
Cederholm T, et al. To create a consensus on malnutrition diagnostic criteria. JPEN J Parenter Enteral Nutr. 2017;41:311–4.
Martin L, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33:90–9.
Schiessel DL, et al. Barriers to cancer nutrition therapy: excess catabolism of muscle and adipose tissues induced by tumour products and chemotherapy. Proc Nutr Soc. 2018;30:1–9.
Loomans HA, et al. Intertwining of activin a and TGFβ signaling: dual roles in cancer progression and cancer cell invasion. Cancers. 2014;7:70–91.
Agustsson T, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007;67:5531–7.
Xue Y, et al. Zinc-α-2-glycoprotein: a candidate biomarker for colon cancer diagnosis in chinese population. Int J Mol Sci. 2015;16:691–703.
Cabassi A, et al. Zinc-α2-glycoprotein as a marker of fat catabolism in humans. Curr Opin Clin Nutr Metab Care. 2013;16:267–71.
Adegoke OAJ, et al. mTORC1 and the regulation of skeletal muscle anabolism and mass. Appl Physiol Nutr Metab. 2012;37:395–406.
Egerman MA, et al. Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol. 2014;49:59–68.
Martin L, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–47.
Blauwhoff-Buskermolen S, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol. 2016;34:1339–44.
Ní Bhuachalla ÉB, et al. Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition?. J Cachex- Sarcopenia Muscle. 2018;9:295–305.3.
Purcell SA, et al. Key determinants of energy expenditure in cancer and implications for clinical practice. Eur J Clin Nutr. 2016;70:1230–8.
Mitchell CJ, et al. The effects of dietary protein intake on appendicular lean mass and muscle function in elderly men: a 10-wk randomized controlled trial. Am J Clin Nutr. 2017;106:1375–83.
Weyermann P, et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS ONE. 2009;4:e4774.
Breit SN, et al. Targeting obesity and cachexia: identification of the GFRAL receptor-MIC-1/GDF15 pathway. Trends Mol Med. 2017;3:1065–7.
Temel JS, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–31.
Prado CMM, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012;106:1583–6.
Pappalardo G, et al. Eicosapentaenoic acid in cancer improves body composition and modulates metabolism. Nutrition. 2015;31:549–55.
Di Girolamo FG, et al. Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. Curr Opin Clin Nutr Metab Care. 2014;17:145–50.
Xue H, et al. Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: from preclinical findings to clinical strategy. JPEN J Parenter Enteral Nutr. 2011;35:74–90.
Fridman WH, et al. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–34.
The author receives funding from the Canadian Institutes of Health Research and the Alberta Cancer Foundation.
Conflict of interest
The author declares that they have no conflict of interest.
About this article
Cite this article
Baracos, V.E. Cancer-associated malnutrition. Eur J Clin Nutr 72, 1255–1259 (2018). https://doi.org/10.1038/s41430-018-0245-4
Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms
Cancer Management and Research (2021)
Fibrinogen/Albumin Ratio Index Is an Independent Prognosis Predictor of Recurrence-Free Survival in Patients After Surgical Resection of Gastrointestinal Stromal Tumors
Frontiers in Oncology (2020)
Clinical Oncology Society of Australia: Position statement on cancer‐related malnutrition and sarcopenia
Nutrition & Dietetics (2020)
Cancer-related malnutrition management: A survey among Italian Oncology Units and Patients’ Associations
Current Problems in Cancer (2020)
World Journal of Clinical Cases (2020)